WALTHAM, Mass. OptimizeRx Corp. has announced organizational updates and leadership advancements designed to accelerate the company’s Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the company’s leadership bench and CEO Steve Silvestro’s commitment to aligning talent and structure with OptimizeRx’s long-term strategic objectives under his management.
"Over the past six months, I have had the opportunity to evaluate our organization from the CEO seat and make key decisions to ensure we are positioned to execute with focus, speed, and strategic clarity," said Steve Silvestro, CEO. "These leadership evolutions reflect our confidence in the outstanding talent we have across the business and our commitment to developing and elevating leaders who will drive the next chapter of our profitable growth."
Leadership Advancements:
Ed Stelmakh has been appointed chief financial & strategic officer (CFSO), evolving from his previous responsibilities as the Company’s Chief Financial Officer & Chief Operations Officer to encompass corporate broader strategy alongside financial leadership. This move underscores the Company’s focus on profitable growth and reinforces the importance of shareholder value creation in shaping OptimizeRx’s future. In addition to his financial responsibilities as the CFSO, Mr. Stelmakh will play a key role in helping the Company achieve Rule of 40 in the coming 2-3 years.
Theresa Greco, chief commercial officer (CCO), will continue the oversight of the commercial team, including sales, account management and marketing, and will focus on the Company’s growth plan. Ms. Greco’s leadership and focus on strategy and execution has been a key driver to the Company’s strong year-to-date revenue performance, and she will continue to drive OptimizeRx’s sustainable revenue growth by working towards transitioning to a re-occuring model as a way of creating a more predictable financial profile.
Marion Odence-Ford has been named chief legal & administrative officer (CLAO), reflecting an expanded role that now includes oversight of key administrative functions in addition to her continued leadership of legal, compliance, and governance matters. Ms. Odence-Ford will partner closely with the CEO and CFSO to ensure alignment between legal and strategic initiatives and will also lead the compliance charge for any regulatory and legislative change that could be promulgated in the coming years.
Doug Besch, chief product & technology officer (CPTO), will continue to drive execution of the Company's product and technology strategies through product enhancements and platform optimization. His leadership has been instrumental in the Company’s overall client positioning and ability to capture market share of pharma's commercial spend. In addition to the Company’s product and technology strategies, Dr. Besch will also lead all data and partnership efforts as the Company continues to expand its proprietary omnichannel network to reach both HCP and DTC audiences.
Brendan Merrell has been appointed chief operating officer (COO), advancing from his prior roles of increasing responsibilities in the Company’s commercial operations, including most recently as SVP, Client Strategy & Program Management. This elevation signals both the depth of the Company’s management team and its investment in developing top talent into mission-critical leadership roles. Mr. Merrell will continue to be focused on operational excellence as well as driving more operating leverage as he partners with business leaders and teams across the Company.
Andy D’Silva has been promoted to chief business officer (CBO) from the role of SVP, Corporate Finance. In this expanded role, Mr. D’Silva will be focused on strategic planning initiatives, while continuing leadership over FP&A and investor relations. In executing these increased responsibilities as the CBO, Mr. D’Silva will champion Rule of 40 strategies as the Company accelerates its growth initiatives. This move reflects OptimizeRx’s commitment to tightly aligning financial results and strategic execution.
